Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Breast 1

Conditions

Breast Neoplasms 45Inflammatory Breast Neoplasms 5Breast Neoplasms, Male 5Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Burkitt Lymphoma 4Testicular Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Lymphoma 3Leukemia, Myeloid, Acute 3Carcinoma, Ovarian Epithelial 3Wilms Tumor 2Testicular Germ Cell Tumor 2Sarcoma 2Recurrence 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms 2Melanoma 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Leukemia 2Dendritic Cell Sarcoma, Interdigitating 2

Interventions

Cyclophosphamide 3Pyridoxine 2Amifostine 2trastuzumab deruxtecan 1sodium thiosulfate 1sargramostim 1sacituzumab govitecan 1eribulin 1Triptorelin Pamoate 1Trastuzumab 1Thiotepa 1Social Determinants of Health 1Radiotherapy 1Pregabalin 1Peripheral Blood Stem Cell Transplantation 1Mitoxantrone 1Methotrexate 1Furosemide 1Etoposide 1Epoetin Alfa 1Duloxetine Hydrochloride 1Drug Therapy 1Doxorubicin 1Dihydrouracil Dehydrogenase (NADP) 1Cisplatin 1Chemotherapy, Adjuvant 1Celecoxib 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Peripheral Blood Stem Cell Transplantation × Breast × Clear all
NCT00003068 2013-01-31

High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
30 enrolled
Breast

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡